AscellaHealth Announces Key Executive Promotions, Supporting Strategic Growth in the Life Sciences Business Unit
Globe Newswire • Tue Apr 15 2025
BERWYN, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the promotion of Donovan Quill to chief strategy officer, Life Sciences, and Bob Gilkin, RPh, MBA, to chief commercial and growth officer.
BERWYN, Pa., April 15, 2025 (GLOBE NEWSWIRE) – AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the promotion of Donovan Quill to chief strategy officer, Life Sciences, and Bob Gilkin, RPh, MBA, to chief commercial and growth officer. In their new positions, Donovan and Bob serve dual appointments, continuing in their leadership roles at AscellaHealth while contributing to the growth of Actum Pharma as an affiliate organization that helps companies fund, develop, manage and market novel, life-changing therapies.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.